摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

7-amino-5-(3-hydroxyphenyl)-2,4-dioxo-1,3,4,5-tetrahydro-2H-pyrano[2,3-d]pyrimidine-6-carbonitrile | 365517-22-2

中文名称
——
中文别名
——
英文名称
7-amino-5-(3-hydroxyphenyl)-2,4-dioxo-1,3,4,5-tetrahydro-2H-pyrano[2,3-d]pyrimidine-6-carbonitrile
英文别名
7-Amino-5-(3-hydroxyphenyl)-2,4-dioxo-1,5-dihydropyrano[2,3-d]pyrimidine-6-carbonitrile
7-amino-5-(3-hydroxyphenyl)-2,4-dioxo-1,3,4,5-tetrahydro-2H-pyrano[2,3-d]pyrimidine-6-carbonitrile化学式
CAS
365517-22-2
化学式
C14H10N4O4
mdl
——
分子量
298.258
InChiKey
YSUVKQXJKVKSQO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.3
  • 重原子数:
    22
  • 可旋转键数:
    1
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.07
  • 拓扑面积:
    138
  • 氢给体数:
    4
  • 氢受体数:
    6

反应信息

  • 作为产物:
    参考文献:
    名称:
    吡喃环杂环支架的合成:使用二甲胺的高度方便的协议
    摘要:
    通过在二甲胺存在下通过一锅缩合芳香族醛,丙二腈和不同的可烯丙基化C-H活化酸性化合物,开发了一种可药用的吡喃环杂环的快速简便的三组分合成方法。 -乙醇在温和的反应条件下制得的催化剂。各种吡喃衍生物的选择性取决于烯醇化物的结构。本方案具有合成优势,无需色谱即可在短得多的反应时间内获得优异的收率。
    DOI:
    10.1007/s11164-014-1873-5
点击查看最新优质反应信息

文献信息

  • Three-component synthesis of 4<i>H</i>-pyran scaffolds accelerated by a gabapentin-based natural deep eutectic solvent
    作者:Meysam Alipour Khoshdel、Farhad Shirini、Mohaddeseh Safarpoor Nikoo Langarudi、Mehdi Zabihzadeh、Mohammad Biglari
    DOI:10.1039/d0nj05342b
    日期:——
    catalyst for the synthesis of 4H-pyran scaffolds such as tetrahydrobenzo[b]pyran and pyrano[2,3-d]pyrimidinone(thione) derivatives. The use of inexpensive and bio-compatible reagents for the synthesis of the catalyst, a simple and green procedure for the preparation of the catalyst and products, short reaction times, high yields of the products, and applicability to large-scale synthesis are the prominent
    在最近的有机合成中,对环境无害的合成方法的发展引起了越来越多的关注。作为这一概念的一部分,我们的小组使用加巴喷丁氯化胆碱合成了一种新型的天然深共熔溶剂(NADES)。在通过FTIR,1 H和13 C NMR以及质谱进行表征后,所制备的NADES被用作合成4 H-喃骨架如四氢苯并[ b ]喃和喃并[2,3- d ]的有效催化剂。]嘧啶酮(酮)衍生物。廉价的和生物相容性试剂用于催化剂的合成,用于催化剂和产物的制备的简单且绿色的过程,短的反应时间,产物的高产率以及适用于大规模合成是突出的问题。该协议的功能。而且,该催化剂可以容易地回收并循环多达五次,而不会显着损失其催化活性。
  • Synthesis, biological activity and POM/DFT/docking analyses of annulated pyrano[2,3-d]pyrimidine derivatives: Identification of antibacterial and antitumor pharmacophore sites
    作者:Ajmal R. Bhat、Rajendra S. Dongre、Faisal A. Almalki、Malika Berredjem、Mohamed Aissaoui、Rachid Touzani、Taibi Ben Hadda、Mohammad S. Akhter
    DOI:10.1016/j.bioorg.2020.104480
    日期:2021.1
    on its antimicrobial activity against some Gram-positive and Gram-negative bacteria such as Pseudomonas aureus, E. coli, Staphylococcus aureus, Klebsiella pneumonia and Bacillus cereus. All the pyrano[2,3-d]pyrimidines were characterized by spectroscopic analyses. Antibacterial screening revealed that the presence of heteroaryl, cyano and amino groups on pyrano[2,3-d]pyrimidine skeleton increases its
    合成了新的环状喃并[2,3-d]嘧啶生物,其骨架上带有羟基、甲氧基、、腈和硝基取代基。注意到取代基对抗菌活性大小的相关电子效应。喃并[2,3-d]嘧啶骨架中苯环上的给电子取代基(即:4-OH、4-OCH 3、4-Br)和吸电子取代基(4-NO 2)对其产生不同的影响。对一些革兰氏阳性和革兰氏阴性细菌如黄色葡萄球菌、大肠杆菌、黄色葡萄球菌、肺炎克雷伯菌和蜡状芽孢杆菌的抗菌活性。所有喃并[2,3-d]嘧啶均通过光谱分析表征。抗菌筛选表明,喃并[2,3-d]嘧啶骨架上杂芳基、基和基的存在增加了其对细菌细胞壁的渗透能力,从而使产物变得更具生物活性。因此在药物设计中应考虑吸电子或供电子体的性质对取代基的影响。 -CRN 解为酰胺恢复了重要的分子内相互作用,如邻硝基苯基和 -ONO δ- ...-NH δ+/酰胺链接,为抗菌-NH、H2O-药团位点提供了关键模板,最终提高了先天抗菌谱。由于武装环状喃并
  • Three-component synthesis of pyrano[2,3-d]pyrimidinone derivatives catalyzed by Ni2+ supported on hydroxyapatite-core–shell-γ-Fe2O3 nanoparticles in aqueous medium
    作者:Sobhan Rezayati、Zahra Abbasi、Eshagh Rezaee Nezhad、Rahimeh Hajinasiri、Abdolhadi Farrokhnia
    DOI:10.1007/s11164-016-2555-2
    日期:2016.10
    via one-pot, three-component condensation reaction of aromatic aldehydes, malononitrile, and barbituric acid in aqueous ethanol catalyzed by Ni2+ supported on hydroxyapatite-core–shell-γ-Fe2O3 nanoparticles (γ-Fe2O3@HAp-Ni2+ NPs) as Lewis acid. The nontoxic nature and easy handling of the catalyst, environmentally friendly and facile work-up procedure, short reaction time, low catalyst loading, and
    通过羟基磷灰石-核-壳-γ-Fe负载的Ni 2+催化芳香族醛丙二腈巴比妥酸乙醇溶液中的一锅三组分缩合反应合成了喃并[2,3- d ]嘧啶生物。2个ø 3纳米颗粒(γ-的Fe 2 ö 3 @的HAp-Ni系2+ NPS)作为路易斯酸。该方法的优点是无毒且催化剂易于处理,环保且易于后处理,反应时间短,催化剂用量低以及能以良好至极好的收率生产产品的高效性。另外,γ-的Fe 2 ö 3 @ HAP-的Ni 2+ NP可以轻松回收并重复使用至少六次。
  • Preparation of a new DABCO-based ionic liquid [H 2 -DABCO][H 2 PO 4 ] 2 } and its application in the synthesis of tetrahydrobenzo[ b ]pyran and pyrano[2,3- d ]pyrimidinone derivatives
    作者:Farhad Shirini、Mohaddeseh Safarpoor Nikoo Langarudi、Nader Daneshvar
    DOI:10.1016/j.molliq.2017.03.063
    日期:2017.5
    A new acidic ionic liquid, 1,4-diazabicyclo[2.2.2]octane-1,4-diium dihydrogen phosphate [H2-DABCO][H2PO4]2}, was prepared in a quick and straightforward process and characterized by using different methods such as FT-IR, NMR and Mass analysis. Then it was used as a reusable and new catalyst to promote the synthesis of tetrahydrobenzo[b]pyran and pyrano[2,3-d]pyrimidinone derivatives as important biologically
    一种新型的酸性离子液体,1,4-二氮杂双环[2.2.2]辛烷-1,4-磷酸二氢二氢盐[H 2 -DABCO] [H 2 PO 4 ] 2 },可以通过一种快速而直接的方法制备,并通过使用FT-IR,NMR和质量分析等不同方法进行表征。然后,它被用作可重复使用的新催化剂,以促进四氢苯并[ b ]喃和喃并[2,3- d ]嘧啶酮衍生物的合成,它们是重要的生物活性化合物,被用于制药工业。这种适当的方法具有一些优点,例如以高收率生产目标化合物,反应时间短,后处理步骤简单以及使用主要且易于制备的催化剂。
  • Nano-Zn[2-boromophenylsalicylaldiminemethylpyranopyrazole]Cl<sub>2</sub>as a novel nanostructured Schiff base complex and catalyst for the synthesis of pyrano[2,3-<i>d</i>]pyrimidinedione derivatives
    作者:A.R. Moosavi-Zare、H. Goudarziafshar、Z. Jalilian
    DOI:10.1002/aoc.4584
    日期:2019.1
    several techniques. Nano‐[Zn‐2BSMP]Cl2 was used as an effective catalyst for the preparation of some pyrano[2,3‐d]pyrimidinedione derivatives by the multicomponent reaction of malononitrile, aryl aldehydes and barbituric acid derivatives. The novelty and efficiency of nano‐[Zn‐2BSMP]Cl2 as a catalyst, in comparison with some other reported catalysts, for this synthetic transformation are the main features
    制备了一种新型的纳米结构的席夫碱复合物纳米Zn [2-苯基苯基水杨醛亚胺基甲基喃并吡唑] Cl 2(nano [Zn-2BSMP] Cl 2),并使用多种技术对其进行了表征。纳米[Zn-2BSMP] Cl 2被用作通过丙二腈,芳基醛和巴比妥酸生物的多组分反应制备某些喃并[2,3- d ]嘧啶二酮衍生物的有效催化剂。与其他报道的催化剂相比,纳米[Zn-2BSMP] Cl 2作为催化剂的新颖性和效率是这项工作的主要特征。
查看更多

同类化合物

叔-丁基2-(甲磺酰)-5,7-二氢螺[吡喃并[4,3-D]嘧啶并-8,3-吡咯烷]-1-甲酸基酯 乙基7'-氨基-6-氟-2,2',4'-三羰基-1,1',2,2',3',4'-六氢螺[吲哚-3,5'-吡喃并[2,3-d]嘧啶]-6'-羧酸酯 7H-吡喃并[2,3-d]嘧啶-7-酮 7H-吡喃并[2,3-d]嘧啶 7,8-二氢-5H-吡喃并[4,3-D]嘧啶-2-胺 5H-吡喃并[4,3-d]嘧啶 5H-吡喃并[2,3-d]嘧啶 2H-吡喃并[2,3-d]嘧啶-6-甲腈,7-氨基-1,3,4,5-四氢-5-(4-甲氧苯基)-2,4-二羰基- 2,4-二氯-7,8-二氢-5H-吡喃[4,3-d]嘧啶 1H-吡喃并[3,4-d]嘧啶 1H-吡喃并[3,2-d]嘧啶 (5S,7R,8S)-2-methylsulfanyl-5,8-dihydro-7-allyloxymethyl-5-methoxy-pyrano[3,4-d]-pyrimidin-8-ol 5-ethyl-2-[(Z)-1-thiophen-3-ylpentylideneamino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione 5-ethyl-2-[[1-(3-methylbutanoyl)piperidin-4-ylidene]amino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione 5-butyl-2-[(E)-1-(4-cyclohexylpiperazin-1-yl)butylideneamino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione 2,3,3a,9-tetrahydro-5-iodo-2,3,3-trimethylimidazo[5,1-b][1,3]benzoxazin-1-one 2,4-dimethyl-9-methoxy-4,12b-dihydro-1H,7H-chromeno[4',3'-4,5]pyrano[2,3-d]pyrimidine-1,3(2H)-dione 5-methyl-3-{3-[(R)-2-oxo-3-(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)-oxazolidin-5-yl]-propyl}-1H-quinazoline-2,4-dione 7-amino-2-(benzothiazol-2-ylmethyl)-9-phenylthiazolo[4',5':6,5]pyrano[2,3-d]pyrimidine-8(7H)-one 2-[6-[(2-chlorophenyl)methyl]pyridin-2-yl]-7,8-dihydro-5H-pyrano[4,3-d]pyrimidine 8-amino-2-(methylthio)-5-oxo-6-(pyridin-4-yl)-5,6-dihydro-4H-pyrano[2,3-d][1,3]thiazolo[4,5-b]pyridine-7-carbonitrile 5-(4-chlorophenyl)-1,3,8,8-tetramethyl-7,9-dihydro-5H-chromeno[2,3-d]pyrimidine-2,4,6-trione ethyl 7'-amino-2,4'-dioxo-2'-thioxo-1,1',2,2',3',4'-hexahydrospiroindole-3,5'-pyrano[2,3-d]pyrimidine-6'-carboxylate 8-amino-2-(methylthio)-5-oxo-6-(pyridin-3-yl)-5,6-dihydro-4H-pyrano[2,3-d][1,3]thiazolo[4,5-b]pyridine-7-carbonitrile 7-Amino-4-oxo-5-phenyl-2-thioxo-1,3,4,5-tetrahydro-2H-pyrano[2,3-d]pyrimidine-6-carboxylic acid ethyl ester 3-(1H-benzoimidazol-2-yl)-3-butyl-5-methyl-dihydro-furan-2-one 3-(1H-benzoimidazol-2-yl)-3-(2-diethylamino-ethyl)-5-methyl-dihydro-furan-2-one 1-{4-[(1R,9S)-3-((S)-3-methyl-morpholin-4-yl)-12-oxa-4,6-diaza-tricyclo[7.2.1.0-2,7]dodeca-2(7),3,5-trien-5-yl]-phenyl}-3-oxetan-3-yl-urea (S)-6-(4-(4-(3-ethylmorpholino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl)phenylamino)pyridin-2(1H)-one 3-(1H-benzoimidazol-2-yl)-5-methyl-3-(3-methyl-butyl)-dihydro-furan-2-one 13-(3,4-dimethoxyphenyl)-5,5-dimethyl-2-thioxo-2,5,6,8,9,13-hexahydro-4H-pyrimido[5',4':6,7][1,8]naphthyridino[4,3,2-de]quinazoline-10,12(3a1H,11H)-dione (S)-3-allyl-8-ethyl-4,7-dioxo-2-(phenylcarbamoyl)-4,5,7,8-tetrahydro-3H-pyrano[4,3-d]pyrimidin-8-yl acetate 8-{[(2-bromo-3-methylphenyl)oxy]methyl}-1,3-dimethyl-2,3,4,6-tetrahydro-1H-pyrano[3,2-d]pyrimidine-2,4-dione 9-ethyl-6a-methyl-2-phenyl-8,9-dihydro-oxazolo[2,3-b]pyrimido[4,5-d][1,3]oxazin-5-one (S)-1-cyclobutyl-3-(4-(4-(3-methylmorpholino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl)phenyl)urea (S)-2-(4-(4-(3-ethylmorpholino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl)phenylamino)pyrimidin-4(3H)-one (6aRS,10aRS)-4,6,6a,7,8,9,10,10a-octahydro-2,4,6,6-tetramethyl-1H-<2>benzopyrano<3,4-d>pyrimidine-1,3(2H)-dione 5-ethyl-2-[(E)-1-thiophen-3-ylpentylideneamino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione N3-(methyl 4-deoxy-α-L-threo-hex-4-enopyranosyluronate)-5-fluorouracil 1-{4-[(1S,9R)-3-((S)-3-methyl-morpholin-4-yl)-12-oxa-4,6-diaza-tricyclo[7.2.1.0-2,7]dodeca-2(7),3,5-trien-5-yl]-phenyl}-3-oxetan-3-yl-urea 4,5-dimethyl-12-(4-methoxyphenyl)-2-thioxo-2,4a,7,8,9,10,11,12-octahydrodipyrimido[4,5-b;4',5'-f] [1,8]naphthyridine-9,11-dione 2-[4-[2-hydroxyethyl(methyl)amino]-2-methyl-7-oxopyrimido[5,4-b][1,4]oxazin-8-yl]acetonitrile 5-ethyl-2-[(Z)-1-thiophen-2-ylethylideneamino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione